China Diagnostic Reagent Industry Report, 2012-2014
  • Jan.2013
  • Hard Copy
  • USD $2,200
  • Pages:86
  • Single User License
    (PDF Unprintable)       
  • USD $2,100
  • Code: XJT025
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,300
  • Hard Copy + Single User License
  • USD $2,400
      

China’s diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China’s medical care investment and per capita health care spending, the China’s diagnostic reagent market has a promising prospect.

In vitro diagnostic reagents account for more than 90.0% of the output of China’s diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.

Market Scale of In Vitro Diagnostic Reagent in China, 2007-2015
?20130002.gif

At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in China’s diagnostic reagent market, including KHB and Fosun Pharma; other enterprises such as Da An Gene, BioSino, Leadman and Livzon have competitive advantages in specific fields such as biochemical diagnosis, immunodiagnosis, and molecular diagnosis. Meanwhile, China’s in vitro diagnostic reagent industry concentration is low. Among 300-400 enterprises, there are only about 20 enterprises with annual sales of more than RMB 100 million. The enterprises are generally small and have a few product varieties. In 2011, KHB, Da An Gene, BioSino, Leadman only occupied 3.8%, 2.3%, 1.9%, 1.6% of the market respectively.

As a high-tech industry, the profitability of the overall Chinese diagnostic reagent industry is high. In 2011, among major Chinese diagnostic reagent enterprises, KHB, Da An Gene, BioSino, Kinghawk, Livzon, Leadman all achieved a gross margin of more than 50%; Fosun Pharma reached a gross margin of 40.4%, since diagnostic reagent and instrument business accounts for a lower proportion of its revenue. With the improvement of industry concentration, it’s expected that the advantageous enterprises with strong capability of technological innovation and large production scale will obtain higher market share and profitability.

China Diagnostic Reagent Industry Report, 2012-2014 mainly includes the following contents:

--Market scale, market structure, import and export, competitive landscape, profitability, entry barriers of China’s diagnostic reagent industry;
--Regulatory system and policy, industry policy, industrial chain, upstream and downstream of China’s diagnostic reagent industry;
--Development forecast of China’s diagnostic reagent industry, including the forecast of market scale, major market segments, industry competition, and enterprise development trends;
--Production, operation, investment, M&A, diagnostic reagent business and development prospect of 15 Chinese diagnostic reagent enterprises.

1. Overview of Diagnostic Reagent Industry
1.1 Definition 
1.2 Classification 

2. China Diagnostic Reagent Industry
2.1 Overview 
2.2 Market Structure 
2.3 Import and Export 
2.3.1 Import 
2.3.2 Export 
2.4 Competitive Landscape 
2.4.1 Biochemical Diagnostic Reagents
2.4.2 Immune Diagnostic Reagents
2.4.3 Molecular Diagnostic Reagents
2.4.4 Integrated In Vitro Diagnostic Reagents
2.5 Profitability 
2.6 Entry Barriers
2.6.1 Technical Barriers
2.6.2 Quality and Brand Barriers
2.6.3 Marketing Channel Barriers
2.6.4 Market Access Barriers 

3. Development Environment of China Diagnostic Reagent Industry
3.1 Policy Environment 
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Industries 
3.2.1 Industrial Chain
3.2.2 Upstream
3.2.3 Downstream

4. Development Forecast of China Diagnostic Reagent Industry
4.1 Overall Forecast 
4.1.1 Market Demand Drivers
4.1.2 Market Scale Forecast
4.2 Development Trends of Diagnostic Reagent Industry 
4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream
4.2.2 Industry Concentration Will Increase
4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win 

5. Major Chinese Diagnostic Reagent Enterprises 
5.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB) 
5.1.1 Profile
5.1.2 Operation 
5.1.3 Revenue Structure 
5.1.4 Gross Margin 
5.1.5 R & D and Investment 
5.1.6 Customers 
5.1.7 Diagnostic Reagent Business 
5.1.8 Forecast and Prospect
5.2 Da An Gene Co., Ltd.
5.2.1 Profile
5.2.2 Operation 
5.2.3 Revenue Structure 
5.2.4 Gross Margin 
5.2.5 R & D and Investment 
5.2.6 Diagnostic Reagent Business 
5.2.7 Forecast and Prospect
5.3 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.3.1 Profile
5.3.2 Operation 
5.3.3 Revenue Structure 
5.3.4 Gross Margin 
5.3.5 R & D and Investment 
5.3.6 Diagnostic Reagent Business 
5.3.7 Forecast and Prospect
5.4 BioSino Bio-technology and Science Inc.
5.4.1 Profile
5.4.2 Operation 
5.4.3 Revenue Structure 
5.4.4 R & D and Investment 
5.4.5 Forecast and Prospect
5.5 Beijing Kinghawk Pharmaceutical Co., Ltd.
5.5.1 Profile
5.5.2 Operation 
5.5.3 Revenue Structure 
5.5.4 Gross Margin 
5.5.5 Diagnostic Reagent Business 
5.5.6 Forecast and Prospect
5.6 Livzon Pharmaceutical Group Inc.
5.6.1 Profile
5.6.2 Operation 
5.6.3 Revenue Structure 
5.6.4 Gross Margin 
5.6.5 Diagnostic Reagent Business 
5.6.6 Forecast and Prospect
5.7 Beijing Leadman Biochemistry Co., Ltd.
5.7.1 Profile
5.7.2 Operation 
5.7.3 Revenue Structure 
5.7.4 Gross Margin 
5.7.5 R & D and Investment 
5.7.6 Customers 
5.7.7 Diagnostic Reagent Business 
5.7.8 Forecast and Prospect
5.8 Acon Biotech (Hangzhou) Co., Ltd.
5.8.1 Profile
5.8.2 Operation 
5.8.3 Development 
5.9 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
5.9.1 Profile
5.9.2 Operation 
5.9.3 Development 
5.10 Shanghai Rongsheng Biotech Co., Ltd. (Rsbio)
5.10.1 Profile
5.10.2 Operation 
5.10.3 Development 
5.11 Shenzhen PG Biotech Co., Ltd.
5.11.1 Profile
5.11.2 Operation 
5.12 Shanghai Upper Bio-Tech Pharma Co., Ltd.
5.12.1 Profile
5.12.2 Operation 
5.12.3 Development 
5.13 Inverness Medical (Shanghai) Co., Ltd.
5.13.1 Profile
5.13.2 Operation 
5.14 Blue Cross Bio-Medical (Beijing) Co., Ltd.
5.14.1 Profile
5.14.2 Operation 
5.14.3 Development 
5.15 Beijing North Institute of Biological Technology (BNIBT)
5.15.1 Profile
5.15.2 Operation 
5.15.3 Development 

Classification of In Vitro Diagnostic Reagents by Test Principle/Method
In Vitro Diagnostic Reagent Categories and Products by National Policy
Revenue of China’s Biological Product Industry, 2005-2012 
Market Scale of China’s In Vitro Diagnostic Reagent Industry, 2007-2011 
Market Structure of China’s In Vitro Diagnostic Reagent Industry, 2011 
China’s Import Volume of Diagnostic Reagent, 2007-2012 
China’s Import Value of Diagnostic Reagent, 2007-2012 
China’s Import Price of Diagnostic Reagent, 2007-2012 
China’s Import Volume, Import Value and Unit Import Price of Diagnostic Reagent by Country/Region, 2011 
China’s Export Volume of Diagnostic Reagent, 2007-2012 
China’s Export Value of Diagnostic Reagent, 2007-2012 
China’s Average Export Price of Diagnostic Reagent, 2007-2012 
China’s Export Volume, Export Value and Unit Export Price of Diagnostic Reagent, 2011
Competitive Landscape of China’s Diagnostic Reagent Industry
Diagnostic Reagent Business Revenue of Major Enterprises in China, 2011
Market Share of Major Enterprises in China’s Diagnostic Reagent Industry, 2011
Consolidated Gross Margin of Major Enterprises in China’s Diagnostic Reagent Industry, 2008-2012 
Major Regulatory Policies in China’s Diagnostic Reagent Industry, 2001-2012 
Main Policies in China’s Diagnostic Reagent Industry, 2005-2012 
Diagnostic Reagent Industry Chain 
China’s Hospital Quantity, 1980-2011
China’s Hospital Quantity by Grade, 2011
China’s Medical and Health Expenses, 1980-2011
China’s Medical and Health Expenses as a Percentage of GDP, 1985-2010
Total Personal Health Expenditure of Residents in China, 1980-2010
Per Capita Health Care Spending of China’s Urban and Rural Residents, 1990-2010
Per Capita Health Care Spending of China’s Urban and Rural Residents as a Percentage of Consumer Expenditure, 1990-2010
China’s Hospital Diagnosis and Treatment Quantity, 2005-2011
China’s Hospital Admissions, 2005-2011
China’s Population Aged above 65 and % of Total Population, 1982-2010
China’s Bi-weekly Incidence of Disease by Age 
Market Scale of China’s In Vitro Diagnostic Reagent Industry, 2007-2015
Diagnostic Reagent Product Structure of Mature Market, 2011
Market Scale of Major In Vitro Diagnostic Reagent Varieties in China, 2008-2012
Products and Revenue of Global Major Diagnostic Reagent Manufacturers
Development Course of Roche Diagnostics
Integrated Development Strategy of Global Leading Diagnostic Reagent Company
Revenue and Net Income of KHB, 2008-2012 
Revenue of KHB by Product, 2008-2012 
Revenue of KHB by Region, 2010-2012 
Gross Margin of KHB by Product, 2008-2012 
R&D Expenditure and % of Revenue of KHB, 2008-2012 
Sales of KHB from Top 5 Customers, 2008-2012
Name List, Revenue Contribution and % of KHB’s Top 5 Customers, 2011
Main Products and Time to Market of KHB, 1989-2012
Main Businesses and Products of KHB, 2011
Medical Equipment Types and Products of KHB, 2012
Growth Rates of KHB’s Diagnostic Reagent Revenue and National Diagnosis and Treatment Quantity, 2005-2011
Revenue and Net Income of KHB, 2011-2014 
Revenue and Net Income of Da An Gene, 2008-2012 
Revenue of Da An Gene by Product, 2008-2012 
Revenue of Da An Gene by Region, 2008-2012 
Gross Margin of Da An Gene by Product, 2008-2012 
R&D Expenditure and % of Revenue of Da An Gene, 2008-2012 
New Product Approval Document Type and Quantity of Da An Gene, 2007-2012
Main Assets and Businesses of Da An Gene 
Industrial Chain of Da An Gene 
Revenue and Net Income of Da An Gene, 2011-2014
Revenue and Net Income of Fosun Pharma, 2008-2012 
Revenue of Fosun Pharma by Product, 2008-2012 
Revenue of Fosun Pharma by Region, 2008-2012 
Gross Margin of Fosun Pharma by Product, 2008-2011 
R&D Expenditure and % of Revenue of Fosun Pharma, 2008-2012 
Revenue and Net Income of Fosun Pharma, 2011-2014 
Revenue and Profit of BioSino, 2008-2012
Revenue of BioSino by Product, 2008-2012 
R&D Expenditure and % of Revenue of BioSino, 2008-2012 
Revenue and Profit of BioSino, 2011-2014
Revenue and Net Income of Kinghawk, 2008-2012 
Revenue of Kinghawk by Product, 2010-2012 
Gross Margin of Kinghawk by Product, 2010-2011 
Revenue and Net Income of Kinghawk, 2011-2014 
Revenue and Net Income of Livzon, 2008-2012
Revenue of Livzon by Product, 2008-2012 
Revenue of Livzon by Region, 2008-2012
Gross Margin of Livzon by Product, 2008-2011
Main Diagnostic Reagent Products of Livzon
Revenue and Net Income of Livzon, 2011-2014
Revenue and Net Income of Leadman, 2008-2012
Revenue of Leadman by Product, 2008-2012
Gross Margin of Leadman by Product, 2008-2011
R&D Expenditure and % of Revenue of Leadman, 2008-2012
Sales of Leadman from Top 5 Customers, 2008-2012
Name List, Revenue Contribution and % of Leadman’s Top 5 Customers, 2011
Dealers of Leadman, 2008-2011
Revenue and Net Income of Leadman, 2011-2014
Revenue and Total Profit of Acon, 2007-2009
Gross Margin of Acon, 2007-2009
Total Assets and Liabilities of Acon, 2007-2009
Revenue and Total Profit of Wantai, 2007-2009
Gross Margin of Wantai, 2007-2009
Total Assets and Liabilities of Wantai, 2007-2009
Revenue and Total Profit of Rsbio, 2007-2009
Gross Margin of Rsbio, 2007-2009
Total Assets and Liabilities of Rsbio, 2007-2009
Revenue and Total Profit of PG Biotech, 2007-2008
Gross Margin of PG Biotech, 2007-2008
Total Assets and Liabilities of PG Biotech, 2007-2008
Revenue and Total Profit of Upper Bio-Tech, 2008-2009
Gross Margin of Upper Bio-Tech, 2008-2009
Total Assets and Liabilities of Upper Bio-Tech, 2008-2009
Revenue and Total Profit of Inverness Medical (Shanghai), 2007-2009
Gross Margin of Inverness Medical (Shanghai), 2007-2009
Total Assets and Liabilities of Inverness Medical (Shanghai), 2007-2009
Revenue and Total Profit of Blue Cross, 2007-2009
Gross Margin of Blue Cross, 2007-2009
Total Assets and Liabilities of Blue Cross, 2007-2009
Revenue and Total Profit of BNIBT, 2007-2009
Gross Margin of BNIBT, 2007-2009
Total Assets and Liabilities of BNIBT, 2007-2009

China Diagnostic Reagent Industry Report, 2011-2012

Diagnostic reagent can be divided into in vitro diagnostic (IVD) reagent and in vivo diagnostic reagent, wherein the former always holds a larger market share in China, accounting for 92.6% in the ove...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

China CT Industry Report, 2012-2014

Along with the in-depth implementation of new medical reform, the potential demand in central and western China and rural areas has been further released, and the medical diagnosis, monitoring and tre...

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号